Stand Up To Cancer announced a second SU2C Catalyst collaboration with Genentech, a member of the Roche Group, aimed at accelerating the development of new cancer treatments and combination therapies through clinical trials using Genentech medicines, including both commercial and pre-commercial treatments.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
